Litcius/Paper detail

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Rachel M. Layman, Hyo S. Han, Hope S. Rugo, Erica Stringer-Reasor, Jennifer M. Specht, Elizabeth Claire Dees, Peter Kabos, Samuel Suzuki, Sarah C. Mutka, Brian Sullivan, Igor Gorbatchevsky, Robert Wesolowski

2024The Lancet Oncology42 citationsDOI

Topics & Concepts

PalbociclibBreast cancerOncologyMedicineCancerEndocrine systemInternal medicineHormone receptorHER2 negativeHormoneEndocrinologyGynecologyMetastatic breast cancerAdvanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study | Litcius